文献速递临床试验与 GCP流行病学与生物统计

非心脏手术患者直接口服抗凝药与低分子肝素血栓预防的获益与危害:随机试验的系统综述与网状Meta分析

Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials.
PubMed 文献 · BMJ · 2022-03-09

该系统综述与网状Meta分析纳入68项随机对照试验共45445例非心脏手术患者,比较直接口服抗凝药与低分子肝素用于血栓预防的获益与危害。低剂量和高剂量低分子肝素及直接口服抗凝药均较无主动治疗降低症状性静脉血栓栓塞,但大出血风险增加2-3倍;直接口服抗凝药较预防性低分子肝素可能更大程度预防症状性静脉血栓栓塞。

要点

  • 低剂量、高剂量低分子肝素和直接口服抗凝药较无主动治疗均降低症状性静脉血栓栓塞,证据确定性中至高。
  • 直接口服抗凝药与低分子肝素较无主动治疗大出血风险增加2-3倍,证据确定性中至高。
  • 直接口服抗凝药较预防性低分子肝素降低症状性静脉血栓栓塞且未增加大出血。

核心结论

  • 直接口服抗凝药和低分子肝素较无主动治疗降低静脉血栓栓塞,但可能以相似程度增加大出血。
  • 直接口服抗凝药可能较预防性低分子肝素更大程度预防症状性静脉血栓栓塞。

研究设计与样本

  • 系统综述与随机对照试验网状Meta分析,检索Medline、Embase和Cochrane CENTRAL截至2021年8月。
  • 纳入68项随机对照试验共45445例非心脏手术患者,包括51项骨科、10项普通外科、4项妇科、2项胸科和1项泌尿外科手术。
  • 采用频率学派网状Meta分析多变量随机效应模型,提供比值比及95%置信区间,并用GRADE评估证据确定性。

主要发现

  • 低剂量低分子肝素(OR 0.33,95%CI 0.16至0.67)、高剂量低分子肝素(OR 0.19,95%CI 0.07至0.54)和直接口服抗凝药(OR 0.17,95%CI 0.07至0.41)较无主动治疗降低症状性静脉血栓栓塞,绝对风险差为每1000例1至100例,取决于基线风险,证据确定性中至高。
  • 无一种主动药物降低症状性肺栓塞,证据确定性低至中。
  • 直接口服抗凝药和低分子肝素较无主动治疗大出血比值增加2-3倍,证据确定性中至高,高危患者绝对风险差高达每1000例50例。
  • 高剂量低分子肝素较低剂量低分子肝素未降低症状性静脉血栓栓塞(OR 0.57,95%CI 0.26至1.27)但增加大出血(OR 1.87,95%CI 1.06至3.31)。
  • 直接口服抗凝药较低剂量低分子肝素降低症状性静脉血栓栓塞(OR 0.53,95%CI 0.32至0.89)且未增加大出血(OR 1.23,95%CI 0.89至1.69)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically compare the effect of direct oral anticoagulants and low molecular weight heparin for thromboprophylaxis on the benefits and harms to patients undergoing non-cardiac surgery. DESIGN: Systematic review and network meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), up to August 2021. REVIEW METHODS: Randomised controlled trials in adults undergoing non-cardiac surgery were selected, comparing low molecular weight heparin (prophylactic (low) or higher dose) with direct oral anticoagulants or with no active treatment. Main outcomes were symptomatic venous thromboembolism, symptomatic pulmonary embolism, and major bleeding. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for network meta-analyses. Abstracts and full texts were screened independently in duplicate. Data were abstracted on study participants, interventions, and outcomes, and risk of bias was assessed independently in duplicate. Frequentist network meta-analysis with multivariate random effects models provided odds ratios with 95% confidence intervals, and GRADE (grading of recommendations, assessment, development, and evaluation) assessments indicated the certainty of the evidence. RESULTS: 68 randomised controlled trials were included (51 orthopaedic, 10 general, four gynaecological, two thoracic, and one urological surgery), involving 45 445 patients. Low dose (odds ratio 0.33, 95% confidence interval 0.16 to 0.67) and high dose (0.19, 0.07 to 0.54) low molecular weight heparin, and direct oral anticoagulants (0.17, 0.07 to 0.41) reduced symptomatic venous thromboembolism compared with no active treatment, with absolute risk differences of 1-100 per 1000 patients, depending on baseline risks (certainty of evidence, moderate to high). None of the active agents reduced symptomatic pulmonary embolism (certainty of evidence, low to moderate). Direct oral anticoagulants and low molecular weight heparin were associated with a 2-3-fold increase in the odds of major bleeding compared with no active treatment (certainty of evidence, moderate to high), with absolute risk differences as high as 50 per 1000 in patients at high risk. Compared with low dose low molecular weight heparin, high dose low molecular weight heparin did not reduce symptomatic venous thromboembolism (0.57, 0.26 to 1.27) but increased major bleeding (1.87, 1.06 to 3.31); direct oral anticoagulants reduced symptomatic venous thromboembolism (0.53, 0.32 to 0.89) and did not increase major bleeding (1.23, 0.89 to 1.69). CONCLUSIONS: Direct oral anticoagulants and low molecular weight heparin reduced venous thromboembolism compared with no active treatment but probably increased major bleeding to a similar extent. Direct oral anticoagulants probably prevent symptomatic venous thromboembolism to a greater extent than prophylactic low molecular weight heparin. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018106181.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Marcucci M, Etxeandia-Ikobaltzeta I, Yang S, et al. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials. BMJ. 2022. PMID: 35264372. doi:10.1136/bmj-2021-066785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。